The March futures contract of Nifty 50 suggests a positive start for domestic equities today. The contract
Lupin: The company has announced the successful completion of an inspection carried out by the UK Medicines and Healthcare products Regulatory Agency at its Pithampur facilities in India. Also, the US FDA has completed a Post-marketing Adverse Drug Experience (PADE) inspection of the company's operations. The inspection closed with no observations.
Zydus Lifesciences: The USDA inspected the manufacturing facility SEZ-1 of Zydus Lifesciences located at Pharmez, Ahmedabad. The inspection was a Pre-Approval Inspection (PAI) as well as a GMP Audit and concluded with three observations. There were no Data Integrity related observations.
Shoppers Stop: The company had approved additional investment of upto Rs 25 crores in Global S$ Beauty Brands
(GSBBL), a wholly owned subsidiary, by way of subscription to Preference Shares of GSBBL, in one or more tranches. Earlier, the company made investments aggregating to Rs 20 crores in the preference share capital of GSBBL, by way of subscription to 2,000 preference shares at a face value of Rs 1,00,000/- each issued by GSBBL.
